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Abstract (209 words) 
Induced pluripotent stem cell (iPSC) technology enables us to investigate various potential 
iPSC-based therapies.  Although the safety of iPSC-derivation has not been completely 
validated, anucleate cells, such as platelets or erythrocytes, derived from iPSCs are promising 
targets.  However, the efficiency of in vitro platelet generation from megakaryocytes (MKs) 
under static culture conditions is lower than is seen in vivo. Here we demonstrate the 
proof-of-concept by a two-dimensional flow culture system that enabled us to increase platelet 
yield from human embryonic stem cell (hESCs) or iPSC-derived MKs using a biomimetic 
artificial blood vessel system. The bioreactor was composed of biodegradable scaffolds with 
ordered arrays of pores made to mimic in vivo bone marrow through salt-leaching.  Within the 
system, two flows in different directions in which the angle between the directions of flow is 
60° but not 90° contributed to suitable pressure and shear stress applied to MKs to promote 
platelet generation.  Generated platelets derived from hESCs or hiPSCs through the bioreactor 
with 60° angle revealed intact integrin IIb3 activation after agonist stimulation.  
Collectively, our findings indicate that two flows in different directions of two-dimensional 
flow culture may be a feasible system for in vitro generation of platelets from pluripotent stem 





Platelets are essential for hemostasis and thrombosis, and also play important roles in 
wound repair, inflammatory reactions, angiogenesis, lymph-vessel separation, and tumor 
metastasis (1).  In humans, approximately 1x10
11
 platelets are produced each day, presumably 
through the cytoplasmic fragmentation of megakaryocytes (MKs) and/or formation of 
proplatelets, elongated pseudopods that extend from mature MKs and release platelets (2). 
Platelets production requires the commitment of hematopoietic stem cells 
(HSCs)/hematopoietic progenitor cells (HPCs) to the MK lineage, followed by proliferation of 
the progenitors and terminal differentiation.  Ultimately, immature MKs develop a unique 
membrane complex called the demarcation membrane (DM) system, which is thought to serve 
as a membrane reservoir for platelet biogenesis through both direct cytoplasmic rupture and 
elongation of proplatelets (3).  Both of those processes are controlled by the orchestrated 
activities of numerous signaling molecules (3).  A variety of gene-targeted mouse models have 
shed light on the roles played by the transcriptional factors involved in platelet formation, and 
have contributed to the characterization of the linkage between the machinery of MK maturation 
and platelet release (3,4,5,6,7).  However, the actual machinery of platelet release (platelet 
biogenesis) from MKs has not yet been characterized (8). 
The establishment of mouse (9) and human embryonic stem cells (hESCs) (10) and 
human induced pluripotent stem cells (hiPSCs) (11,12) were crucial advances in the area of 
regenerative medicine.  Notably, hiPSC-based platelet generation is a particularly fascinating 
therapy model, in part because blood donors are becoming increasing scarce in most industrial 
countries, including Japan (13).  In addition, because platelets are anucleate, they can be 
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subjected to gamma irradiation prior to their transfusion, which would prevent the occurrence of 
oncogenesis or teratoma formation due to the presence of residual undifferentiated hiPSCs or 
hiPSC-derived cells.  Finally, for patients requiring repeated transfusions, it is important that 
the platelets are human leukocyte antigen (HLA)-matched (13); thus an HLA-identical donor 
could provide the origin cells for creating iPSCs that contribute to a sustained platelet supply.  
Here, by primarily using human ESCs as a gold standard of reference (14, 15), we describe a 
two-dimensional flow culture that recapitulates bone marrow in the view of “blood flow” 
application and may be a feasible system for in vitro generation of platelets from human 






Cells and Reagents 
The KhES-3 human ESC clone (Institute for Frontier Medical Science, Kyoto University, Kyoto, 
Japan) was used upon the approval by the Minister of Education, Culture, Sports, Science, and 
Technology of Japan (MEXT) (14).  In addition, The TkDA3-4 hiPSC clone was used (15). 
The mouse C3H10T1/2 cell line was purchased from the RIKEN Bio-Resource Center (Tsukuba, 
Ibaraki, Japan) and was cultured as described previously (14,15).  Human umbilical cord 
endothelial cells (HUVECs) were purchased from KURABO (Tokyo, Japan).  Human vascular 
endothelial growth factor (VEGF), human thrombopoietin (TPO) and human stem cell factor 
(SCF) were all from R&D Systems (Minneapolis, MN).  Heparin was from Ajinomoto 
Pharmaceuticals Co., LTD (Tokyo, Japan).  The following antibodies and stains were obtained 
from BD Biosciences (Franklin Lakes, NJ): allophycocyanin (APC)-conjugated anti-CD41a, 
FITC-conjugated anti-CD41a (GPIX), anti-CD42b (GPIb) and Hoechst 33342 (blue).  DAPI 
(Vector Laboratories, Burlingame, CA) and Hoechst 33342 were used for nuclear staining in 
MKs. FITC-conjugated PAC-1 antibody (BD Biosciences, San Diego, CA) was used for platelet 
activation studies as described (14, 15). 
 
Hematopoietic differentiation of human ESCs or iPSCs  
Differentiation of human ESCs or iPSCs into hematopoietic cells was performed as described 
previously (14,15).  In brief, small clumps of ESCs or iPSCs (<100 cells treated with PBS 
containing 0.25% trypsin (Invitrogen, Carlsbad, CA), 1 mM CaCl2 (Sigma-Aldrich, St. Louis, 
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MI) and 20% Knock-out Serum Replacement (KSR, Invitrogen [Life technology Japan, Tokyo]) 
were transferred onto mitomycin (Sigma)-treated or irradiated C3H10T1/2 cells and co-cultured 
in hematopoietic cell differentiation medium (Iscove’s Modified Dulbecco’s Medium [IMDM, 
Life technology Japan, Tokyo] with 15% fetal bovine serum and VEGF as described previously 
(14,15), which was replaced every 3 days.  On days 14-15 of culture, the HPCs within ES- 
(14) or iPS-Sacs (15) were collected, transferred onto fresh mitomycin-treated or irradiated 
feeder cells, and further cultivated in differentiation medium supplemented with 50 ng/ml TPO, 
50 ng/ml SCF and 25 U/ml heparin sodium, as described (14,15).  The medium was refreshed 
every 3 days, and non-adherent cells were collected on day 20 of culture and transferred to a 
bioreactor. 
 
Flow cytometric analysis of platelets  
Washed platelets were prepared as described previously (14,15).  The resultant platelet pellets 
were resuspended with staining medium and stained with anti-human CD41a-APC and 
CD42b-PE for 30 min at room temperature.  The platelets were then diluted in 200 l of 
staining medium and analyzed by flow cytometry (FACSAria, BD biosciences, San Diego, CA). 
Platelet numbers were counted using True Count Beads (BD Biosciences). 
 
Construction of a bioreactor to obtain platelets from human iPSC-derived MKs 
The fabrication of a bioreactor to produce platelets entailed the following steps.  Using 
photo-resist SU8-3050 (Nippon Kayaku, Tokyo, Japan), a microfluidic device was constructed 
by centrifugation on a silicon wafer at 5000 rpm for 30 s.  The device was then exposed after 
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applying a mask using a mask aligner, developed in developer and rinsed with de-ionized water.  
Polydimethylpolysiloxane (PDMS) was then solidified on the fabricated mold at 60°C in an 
oven.  Finally, the PDMS was released from the mold and bonded to a glass plate. 
 
Experimental procedure (dissemination of cells, culture and counting platelets)  
Sterilization of the bioreactor was achieved through treatment with ethanol for 30 min 
irradiation with UV light.  Platelet generation in the bioreactor was observed in a connected 
circulation system on the stage of a confocal microscope (FV1000, Olympus, Tokyo, Japan) at 
37°C.  The process of platelet generation from MKs was visualized using a confocal 
microscope system, and the images were recorded in the hard disc of a connected computer.  
Flow pressure was determined by flow speed and the medium collected, including the cell 
populations in the reservoir.  After adding ACD medium to the culture medium (1:10 dilution), 
the collected samples were centrifuged at 900 rpm for 10 min (slow acceleration).  Finally, the 
cell samples were stained for cell surface molecules specific for MKs/platelets and analyzed by 
flow cytometry.  
 
Statistics 




Results and Discussion 
Observations in living mice made using two-photon confocal microscopy revealed that platelet 
release occurs within both the capillaries and sinusoids of the bone marrow (8).  Within human 
bone marrow, sinusoidal capillaries are the discontinuous type, with wall thicknesses less than 
30 m and containing numerous pores.  One approach to reconstituting the structure of such 
vessels in vitro is to use a sheet-like scaffold with multiple pores (16).  We constructed a 
structure using the salt-leaching method as shown in Figure 1A.  The contents of the solution 
used for the salt-leaching are shown in Table 1.  
Using the constructed sheet-like porous structure, we designed the bioreactor to 
recapitulate mainly two functions of capillary blood vessel for platelet production: (i) one 
function that is a porous structure of endothelial cells for fixing MKs on the outside of blood 
vessel wall (17), and, (ii) another function that is a platelet production of MKs by applying the 
shearing effects of blood flow. Within the bioreactor, the membrane scaffold for platelet release 
from MKs was composed of PDMS.  Moreover, the scaffold was completely covered by 
HUVECs where adjacent chamber with a layer of HUVECs and a formed porous barrier in 
between appeared 30 m. By adjusting the speed of flow through the structure, different levels 
of shear stress were generated, which were calculated using equation (A), where Q is flow speed 
[ml/h],  is the viscosity of the medium [Pa/s], a is the width of the duct [5.0 mm], and b is the 






  （A） 
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In the system, the medium flows past MKs on HUVECs in two directions (pressure flow 
and main flow), such that the pressure flow is perpendicular to the main flow; the main flow 
applies shear stress to the MKs, while the pressure flow applies pressure for MK fixation to the 
each slit. Thus we estimated that exposed shear stress was occurred from 0.14-37.5 dyne/cm
2 
onto MKs within chamber and iPSC-derived MKs were applied into the regions of the pores, as 
shown in the left panel of Figure 1B, although it is not ruled out that the flow was turbulence. 
In addition, we expected that vascular cell adhesion molecule-1 (VCAM-1) on HUVEC 
might promote platelet release from MKs because of the reports that integrin 41 expression 
in MKs is crucial for platelet production in vivo in mouse models (reference 18) or that the 
binding between integrin 41 in MKs and VCAM-1 promoted proplatelets, a hallmark of 
platelet generation, from cultured MKs in vitro (19).  
Our bioreactor system enabled us to visualize real-time changes to MKs during culture.  
Time-lapse confocal microscopy revealed that applied iPSC-derived MKs grew on HUVECs 
within the bioreactor (Figure 2A), and the numbers of adherent MKs were greater under weak 
flow conditions (0.14 dyne/cm
2
) (Figure 2B).  We applied 1.2 x 10
5
 MKs totally into the 
bioreactor and approximately 5.2-5.6 x 10
4
 MKs (average=5.42 x 10
4
, Figure 2A) or 5.8-6.5 x 
10
4
 MKs (average=6.2 x 10
4
, Figure 2B) were counted in the absence or presence of flow 
respectively. When we compared the final yield of platelets between the static culture (no flow) 
in a conventional culture dish (14) and our new bioreactor system with flow, as shown in Figure 
3A, we found that platelet generation from human ESC-derived MKs tended to be better in the 
flow system (Figure 3B).  Moreover, time-lapse imaging of the platelet production from MKs 
under flow revealed that increasing the shear stress by adjusting flow speed (1.0 ml/hr) 
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stimulated large-proplatelet (90 min in Figure 4), followed by cytoplasmic fragmentation from 
ESC-derived MKs (92 min in Figure 4).  However, the increase in platelet production was not 
significant (Figure 3B). 
To improve platelet yield, we designed a new bioreactor using two flows with an angle 
between the main and pressure flows.  The schematic in Figure 5A shows the newer design of 
a bioreactor, in which the angle between the directions of flow is 60°.  The platelets were 
generated from MKs placed between the slits.  We again applied 1.2 x 10
5 
MKs for each 
experiment within a newer bioreactor. Under these conditions, the numbers of platelets 
produced from human ESCs were as much as 3.6 times higher than in static culture (mean 
count: 19822 under static vs. 71755 under flow, Figure 5B, from independent 4 experiments, 
p<0.05). These results using the same improved reactor system were confirmed by using human 





populations was also examined by flow cytometer and there was no significant difference 
between static condition and bioreactor (Figure 5C and 5D).  
In order to confirm the functionality by collected platelets through second generation of a 
bioreactor in Figure 5A, agonist-induced integrin activation in platelets was examined. The 
PAC-1 binding, the activated form of an integrin IIb3 after agonist stimulation showed intact 
functionality by hESC- or iPSC-derived platelets (Figure 6), confirming the similarity to the 
previous studies obtained under static conditions (14, 15). 
Using a novel 3-dimensional bioreactor, which enabled us to regulate shear stress through 
application of flow in two directions, we enhanced platelet generation from MKs by subjecting 
the cells to the appropriate levels of shear stress.  Within this system the shear stress created by 
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the main flow could be regulated by the pressure flow.  Furthermore, it appears that an angle of 
60° between the main and pressure flows is optimal.   
This novel conception has the potential to influence a new era of regenerative medicine 
through the use of hESCs or hiPSCs.  In an effort to better understand the underlying 
molecular mechanisms of platelet release and production from MKs, we are attempting to 
mimic previously visualized in vivo platelet production (8), which showed evidence of shear 
stress dependence.  Recently, several groups reported in vitro platelet generation under 
conditions in which high shear stress was produced utilizing one-directional flow (18, 21).  On 
the other hand, our proposed bioreactor makes use of flow in two directions.  We suggest that 
the flow applying pressure to the cells stimulates MK maturation on HUVECs, while the flow 
applying shear stress stimulates platelet generation.  In addition, it appears that the angle 
between those two-directional flow a key for improving production efficiency as exemplified by 
three times difference in comparison between Figures 3 and 5).  This two-direction flow 
strategy is seemingly a feasible approach to the future development of bioreactors able to supply 
platelets derived from human pluripotent stem cells in numbers sufficient for transfusion.  
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Figure 1.  Fabrication process of a sheet-like scaffold and Medium circulation model of 
bioreactor.  
(A) (a) Produce a wax (made of toluenesulfonamide) model.  (b) Wax model was dipped into 
PVA (Polyvinylalcohol) solution and pulled up with a dip coater (pull-up velocity: 1 mm/s).Dip 
coating of PVA onto the wax model was repeated 6 times, and each coating was followed by 
drying at room temperature for 30 minutes.  (c) After an interval of 12 hours, the PVA-coated 
wax model was soaked in acetone. Because of the insolubility of PVA and solubility of wax in 
acetone, the wax was selectively dissolved, leaving the structure of PVA.  (d) The PVA model 
then was coated with the polymer and NaCl particle solution using the dip coater (velocity: 3 
mm/s). To coat the PLCL (poly (L-lactide-co-epsilon-caprolactone)) membrane as uniformly as 
possible, dip coating of polymer solution onto the PVA model was repeated three times in one 
direction and three times in the opposite direction by setting the model upside down.  (e) Dip 
coated PLCL of the second layer in the same way as (d).  (f) Each coating was followed by 
drying at room temperature for 2 minutes. The PLCL-coated PVA models then were soaked in 
deionized (DI) water followed by dissolution of PVA and the NaCl microparticles. After PVA 
and the NaCl microparticles were completely removed from the PLCL, the salt-leached PLCL 
scaffold was dried for 24 hours at room temperature. 
(B) Culture within the reactor system was performed at 37°C in a CO2 incubator. Circulation 
was achieved using a PFA tube connected to a roller pump to produce flow. The left side 
schematic shows the cross-sectional view of bioreactor. Human umbilical vascular endothelial 
cells (HUVECs) were pre-applied for stable adhesion to the micropores in the scaffold 2 days 
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before the megakaryocytes (MKs) were applied.   
 
Figure 2.  Confocal microscope images of megakaryocytes  (A) Static culture.  (B) Flow 
culture in which the shear stress produced with the reactor system depicted in Figure 2 was 0.14 
dyne/cm
2
.  Nuclei were stained with DAPI (blue) and CD41a was stained with anti-human 
CD41a-FITC (green).  Low-magnification images (left top) shows only DAPI staining. Bars, 
50 m. 
 
Figure 3.  Original model of the bioreactor and comparison of platelet yield (static vs. 
reactor) using the bioreactor system. 
(A) The bioreactor was 25 mm x 28 mm and contained numerous circuits for flow.  The 
termination of each circuit was a pore (~8 m) formed by a pocket containing a single MK.  
MKs were stimulated to mature by the pressure flow, while platelet release was stimulated by 





counts per reservoir (over a period of 12 h).  Black bars show the platelet counts obtained 
under static conditions using the protocol described in ref. 14.  Gray bars show the platelet 
counts obtained using the first generation bioreactor. Number of platelets from static condition 
equalized 1.0. The input was 1.2 x 10
5
 mature MKs in both conditions.  
 
Figure 4. Confocal micrographs showing the time course of a platelet release from a MK 
(green: CD41a, blue: Hoechst).  Nuclei were stained with Hoechst. 
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Figure 5.  Schematic of an improved bioreactor with two-directional flow (second type of 
a bioreactor) and comparison of platelet yields (static vs. reactor). 
(A) The illustration shows the design of a bioreactor with two-directional flow in which the 
angle between the directions of the main and pressure flow is 60°.  Platelets were generated 
from MKs placed between the slits.  The slits were 16 m wide with 4 m in between.  





platelet population counts per reservoir (over a period of 12 h).  Black bars show the platelet 
counts obtained under static conditions using the protocol described in ref. 14.  Gray bars show 
the platelet counts obtained using second generation of a bioreactor.  Average number of 
platelets from static condition equalized 1.0. The input was 1.2 x10
5
 mature MKs in both 
conditions. Experiments were mean+/-s.e.m. (n=4). (C) Representative dot plots of platelets in 
flow cytometer, derived from human ESCs through second generation of a bioreactor (right).  
Same gate in side scatter (SSC) and forward scatter (FSC) of fresh human platelets was used for 
ESC-derived platelets in flow cytometer (left). This gate was re-analyzed for detection of 
CD41a (integrin IIb) and CD42b (GPIb). (D) Purity of CD41a+ or CD41a+CD42b+ platelet 
population of gated population depicted in the left panel of Figure 5C (SSC and FSC) was also 
evaluated as comparison between static culture condition and bioreactor. Black column 





 population.  
 
Figure 6.  Integrin activation of human ESC- or iPSC-platelets.  Integrin activation in 
ESC-platelets (KhES-3) (A) and in iPSC-platelets (TkDA3-4)(B).  The binding of PAC-1 
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(indicative of platelet activation) to individual platelets was quantified in the absence and 
presence of 50 M ADP, 0.5 Unit human Thrombin, or 200 nM phorbol myristate acetate 
(PMA) using flow cytometry. Mean fluorescence intensity (MFI) of bound PAC-1, obtained 
from CD42b
+










 Table 1: Solution used in Salt-Leaching 
 Solution 1 Solution 2 




NaCl:PLCL 20:1 10:1 
Chloroform:PLCL 100:3 100:3 
 
